Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 29;20(1):171.
doi: 10.1186/s12955-022-02064-z.

Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer

T M Ripping  1 , E Rammant  2   3 , J A Witjes  4 , N K Aaronson  5 , M van Hemelrijck  2 , L M C van Hoogstraten  1 ; BlaZIB study group; L A Kiemeney  6 , K K H Aben  7   8
Collaborators, Affiliations

Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer

T M Ripping et al. Health Qual Life Outcomes. .

Abstract

Background: Quality of Life (QoL) of bladder cancer patients has been largely neglected. This is partly due to the lack of well-validated QoL questionnaires. The aim of this study is to examine the structural validity, reliability (i.e., internal consistency and test-retest reliability), construct validity (i.e., divergent validity and known group validity) and responsiveness of the Dutch version of the European Organisation for Research and Treatment of Cancer QoL questionnaire for muscle invasive bladder cancer (EORTC-QLQ-BLM30).

Methods: Patients with newly diagnosed muscle invasive bladder cancer (MIBC) participating in the population-based 'Blaaskankerzorg In Beeld' (BlaZIB) study who completed the EORTC-QLQ-BLM30 at baseline were included. BlaZIB is a Dutch nationwide population-based prospective cohort study collecting clinical data and QoL data of bladder cancer patients. QoL is assessed with a self-administered questionnaire at four points in time: 6 weeks (baseline), 6 months, 12 months and 24 months after diagnosis. Confirmatory factor analysis and multitrait scaling analysis were used to investigate and adapt the scale structure. Reliability, construct validity and responsiveness of the revised scales were evaluated.

Results: Of the 1542 patients invited to participate, 650 patients (42.2%) completed the QLQ-BLM30 at baseline. The questionnaire's scale structure was revised into seven scales and eight single items. Internal consistency and test-reliability were adequate for most scales (Cronbach's α ≥0.70 and intraclass correlation coefficient ≥ 0.70, respectively), with the exception of the revised urostomy problem scale and abdominal bloating and flatulence scale. The questionnaire exhibited little overlap with the EORTC-QLQ-C30: all correlations were < 0.40, except for the correlation between emotional function (QLQ-C30) and future worries (QLQ-BLM30). The questionnaire was able to distinguish between patient subgroups formed on the basis of physical function, but not - as hypothesized- based on stage. Changes in health due to treatment were captured by the questionnaire, indicating that the questionnaire is responsive to change.

Conclusions: This study shows that the adapted scale structure of the EORTC-QLQ-BLM30 generally exhibits good measurement properties in Dutch patients, but needs to be validated in other languages and settings.

Trial registration: BlaZIB, NL8106, www.trialregister.nl.

Keywords: Bladder cancer; EORTC questionnaire; Patient-reported outcomes measures; Quality of life; Validation studies.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Flowchart. HRQoL = Quality of Life; NMIBC = Non-Muscle Invasive Bladder Cancer; MIBC = Muscle Invasive Bladder Cancer; wk. = week; mo = month. aPercentage of patients that completed the questionnaire after being invited to fill in the questionnaire
See this image and copyright information in PMC

References

    1. Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–1904. doi: 10.1007/s00345-019-02984-4. - DOI - PMC - PubMed
    1. Singer S, Ziegler C, Schwalenberg T, Hinz A, Gotze H, Schulte T. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer. 2013;21(5):1383–1393. doi: 10.1007/s00520-012-1680-8. - DOI - PubMed
    1. National Centre for Health and Care Excellence (NICE). Bladder cancer diagnosis and management [NG2]. Retrieved from https://www.nice.org.uk/guidance/ng2 (2015, February 25).
    1. Gilbert SM, Dunn RL, Hollenbeck BK, Montie JE, Lee CT, Wood DP, Wei JT. Development and validation of the bladder Cancer index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol. 2010;183(5):1764–9. 10.1016/j.juro.2010.01.013. - PubMed
    1. Anderson CB, Feurer ID, Large MC, Steinberg GD, Barocas DA, Cookson MS, Penson DF. Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt cystectomy index. Urology. 2012;80(1):77–83. doi: 10.1016/j.urology.2012.01.090. - DOI - PubMed